START FREE TRIAL
Home Healthcare West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

$19.00

SKU: WST-1 Category:

Description

West Pharmaceutical’s GLP-1 Boom — Could Its $3.42 Billion Revenue Target Be Just the Start?

 

West Pharmaceutical Services, Inc. reported a third-quarter performance characterized by strong top-line growth and improved profitability, driven largely by its Proprietary Products segment. Revenues reached $874 million, reflecting an organic increase of 12%, while adjusted earnings per share grew 36% year over year to $2.66, surpassing prior guidance. The company raised its full-year revenue forecast to $3.41-$3.42 billion, representing 11.3%-11.6% organic growth, up from a previous range of 10%-11%. Adjusted EPS guidance was also increased to between $9.38 and $9.48, signifying nearly 30% growth compared to 2025. The Proprietary Products segment, accounting for a majority of revenues, expanded by 16.6% organically. Within this segment, high-value-added polymer (HVP) components showed robust 20% growth fueled by demand for both GLP-1 and non-GLP-1 components, regulatory-driven upgrades, and favorable product mix shifts. HVP GLP-1 product revenues alone grew well into the 30% range organically.